🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 4 quarters analysed

Q2 2025

Confident Specific

Management repeatedly used phrases like 'record high RBR', 'strong demand', 'solid pipeline', and provided specific percentages (8% RBR growth, 4.2% organic). They acknowledged challenges (digital slowdown, regulatory uncertainty) but framed them as temporary, backed by updated guidance increase.

Q3 2025

Confident Specific

Management used consistently positive language such as 'record RVR across all segments', 'strongest environment for performance improvement', 'robust demand', and 'broad-based growth', referencing specific growth rates and affirmations of guidance.

Q4 2025

Confident Specific

The tone is consistently positive and specific throughout the call. Management repeatedly cited 'record RBR' in healthcare and commercial segments, 'fifth consecutive year of margin expansion', 'strongest backlog coverage in five years', and gave explicit guidance figures (e.g., 9.5% RBR growth midpoint, 14.5%-15% EBITDA margin). There is no defensiveness or hedging.

Q1 2026 latest

Confident Specific

Management repeatedly used language like 'execution of our growth strategy continues to deliver performance consistent with the financial goals', 'encouraged by the strong start', 'affirming our annual guidance', and 'bullish on AI'. The tone was assured and forward-looking without hedging.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis appears stronger after this call. The strong Q1 performance with 12% RVR growth, record Healthcare revenue, and 20%+ bookings growth across segments indicates sustained demand. Management reaffirmed all guidance, and the accelerated share repurchases at a lower share price signal confidence. The bullish stance on AI and mention of partnerships suggest a growing tailwind. Key areas to watch next quarter include digital growth recovery in Healthcare and Commercial (management expects mid- to high-single-digit growth later in the year), resolution of DSO on large healthcare projects, and tangible progress on AI revenue. Overall, execution remains solid and supportive of long-term targets.

AI-generated concall tone analysis · Updated 2026-06-09 · Not investment advice

🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →

📊 MIXED Huron Q1 2026: RVR $443.7M (+12%), Healthcare record, affirms guidance.

Revenue & Profitability

Q1 2026 RVR increased 12.1% to $443.7 million from $395.7 million. Net income was $23.2 million ($1.34 per diluted share), compared to $24.5 million ($1.33 per share) in Q1 2025. Adjusted EBITDA was $50.6 million (11.4% of RVR). Healthcare RVR grew 13.5% (10% organic), Commercial RVR grew 22.3% (8% organic), and Education RVR grew 3.8%.

Outlook

Management sees strong secular tailwinds across all segments: healthcare providers face declining reimbursements, rising costs, and labor shortages driving demand for performance improvement and AI; higher education institutions confront funding declines, regulatory scrutiny, and need for digital transformation; commercial clients navigate cost inflation, supply chain realignment, and AI adoption. The company is well-positioned with strong pipelines and backlog.

Growth Drivers

Key growth drivers include strong demand for performance improvement, revenue cycle management, financial advisory, and strategy offerings in Healthcare (14% RVR growth, 10% organic); digital offerings in Education; and financial advisory and strategy in Commercial (22% growth, 8% organic). Acquisitions (Eclipse Insights, AXIA Consulting, Treliant, Wilson Perumal) contributed incremental growth. AI capabilities are seen as a significant future contributor.

Balance Sheet & CapEx

In Q1 2026, Huron invested $11.9 million in capital expenditures, including internally developed software. Full-year free cash flow is expected to be between $180 million and $220 million. The company continues to invest organically in AI capabilities and talent, particularly in healthcare managed services.

Margins

Adjusted EBITDA margin improved to 11.4% of RVR in Q1 2026 from 10.5% in Q1 2025. Full-year adjusted EBITDA margin guidance is 14.5%-15%. Segment margins: Healthcare flat at 28.4%; Education increased to 21.6% from 18.8% due to lower compensation and meeting expenses; Commercial increased to 16.4% from 15.2% due to lower contractor expenses and revenue growth outpacing bonus expense. Unallocated corporate expenses increased $7.9 million excluding deferred compensation.

Key Risks

Risks mentioned include ongoing pressures in healthcare (declining reimbursements, rising costs, labor shortages), education funding declines and regulatory scrutiny, and geopolitical and regulatory uncertainty in commercial markets. DSO increased to 82 days due to performance-based fee elements in larger healthcare projects. The company's leverage ratio was 3.1x at Q1 end, though seasonal, and is targeted to reduce to 2x-2.5x by year-end.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-07-28

Record Q2 2026 results featured 16% revenue growth, margin expansion, and strong cash flow, driven by AI-enabled digital and managed services across all segments. Full-year guidance was raised, with robust outlooks for Healthcare, Education, and Commercial segments.

Q1 2026 Q1 2026 2026-05-05

Q1 2026 saw 12% RBR growth, margin expansion, and record Healthcare performance. Guidance for 2026 is affirmed, with strong pipelines and robust bookings across all segments. Share repurchases accelerated, and AI investment remains a key growth driver.

Q4 2025 Q4 2025 2026-02-24

Record revenue and margin expansion in 2025, with strong growth across all segments and a robust start to 2026. Guidance for 2026 anticipates continued double-digit EPS growth, margin improvement, and significant investment in AI and digital capabilities.

Q3 2025 Q3 2025 2025-10-28

Record Q3 revenue and margin expansion were driven by strong demand across all segments, with healthcare and commercial segments posting double-digit growth. Guidance was raised for adjusted EPS, and robust pipelines support continued growth into 2026.

Q2 2025 Q2 2025 2025-07-31

Second quarter 2025 saw record revenue growth across all segments, with strong demand in healthcare, education, and commercial markets. Full-year guidance was raised, reflecting confidence in continued growth, supported by recent acquisitions and robust sales pipelines.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.